Schedule

4 days, 13 sessions across 3 tracks

Showing 13 of 13 sessions

09:00
Translational Medicine

Precision Oncology: From Biomarker to Bedside

105 minHall B (L2-HALL-B)
DRKMPR
Daniel Reyes, Kwame Mensah, Priya Raman
  • 09:00Circulating Tumour DNA as a Guide to Adjuvant Therapy — Priya Raman
  • 09:35Biomarker-Stratified Trials That Actually Answer the Question — Daniel Reyes
  • 10:10Paying for Precision: The Economics of Molecular Testing — Kwame Mensah
09:15
Clinical Practice

Nurse-Led Models of Chronic Care

75 minSeminar Room 2.2 (L2-SEM-2)
SWAO
Sarah Whitfield, Amara Okafor
  • 09:15Building a Nurse-Led Heart Failure Service — Sarah Whitfield
  • 09:55Telehealth Titration in Type 2 Diabetes — Sarah Whitfield, Amara Okafor
09:30
Research Methods

Real-World Evidence: Getting Regulators to Yes

90 minSeminar Room 2.1 (L2-SEM-1)
HSRG
Hiroshi Sato, Rachel Goldberg
  • 09:30From Registry to Label Extension: A Worked Example — Hiroshi Sato
  • 10:15Real-World Evidence From the Reviewer’s Chair — Rachel Goldberg
11:10
Translational Medicine

Pharmacogenomics at the Point of Prescribing

75 minSeminar Room 2.2 (L2-SEM-2)
LOKMTN
Liam O’Connell, Kwame Mensah, Tomasz Nowak
  • 11:10Pre-emptive Pharmacogenomic Testing Across Three Hospitals — Liam O’Connell
  • 11:35Decision Support That Prescribers Do Not Ignore — Liam O’Connell, Tomasz Nowak
  • 12:00Is Pre-emptive Genotyping Worth It? — Kwame Mensah
11:15

Industry Symposium: Point-of-Care Diagnostics at the Bedside

Presented by Helix DiagnosticsSponsored
135 minHall A (L1-HALL-A)
11:30
Research Methods

Adaptive Trial Designs in Practice

60 minHall B (L2-HALL-B)
DRRG
Daniel Reyes, Rachel Goldberg
  • 11:30Running a Platform Trial: Five Lessons From the First Three Arms — Daniel Reyes
  • 12:00What Regulators Look for in an Adaptive Design — Rachel Goldberg
11:40
Clinical Practice

Antimicrobial Stewardship on the Ward

60 minSeminar Room 2.1 (L2-SEM-1)
FALO
Fatima Al-Sayed, Liam O’Connell
  • 11:40Shorter Antibiotic Courses: The Evidence and the Pushback — Fatima Al-Sayed
  • 12:10Rapid Diagnostics as a Stewardship Tool — Fatima Al-Sayed, Liam O’Connell
13:00
Research Methods

Digital Endpoints and Wearables in Clinical Trials

90 minSeminar Room 2.2 (L2-SEM-2)
TNRGHS
Tomasz Nowak, Rachel Goldberg, Hiroshi Sato
  • 13:00Validating a Wearable-Derived Endpoint — Tomasz Nowak
  • 13:45Decentralised Trials: What Changed After the Pandemic — Rachel Goldberg, Hiroshi Sato
13:05
Clinical Practice

Cardiometabolic Risk: What the New Evidence Changes

90 minHall B (L2-HALL-B)
AOSW
Amara Okafor, Sarah Whitfield
  • 13:05Lower Is Better? Revisiting LDL Targets After the Latest Outcome Trials — Amara Okafor
  • 13:35GLP-1 Receptor Agonists in the Cardiology Clinic — Amara Okafor, Sarah Whitfield
  • 14:05Nurse-Led Follow-Up After a Cardiac Event — Sarah Whitfield
13:15
Translational Medicine

Single-Cell Atlases in Translational Immunology

90 minSeminar Room 2.1 (L2-SEM-1)
MCER
Mei Chen, Elena Rossi
  • 13:15Mapping Tissue-Resident Immunity at Single-Cell Resolution — Mei Chen
  • 14:00From Atlas to Target: Choosing What to Engineer — Elena Rossi, Mei Chen
15:05
Clinical Practice

Paediatric Infectious Disease: Lessons From Three Winters

90 minSeminar Room 2.2 (L2-SEM-2)
FA
Fatima Al-Sayed
  • 15:05RSV and Influenza Surveillance in Children, 2023–2026 — Fatima Al-Sayed
  • 15:50Planning Paediatric Surge Capacity — Fatima Al-Sayed
15:10
Translational Medicine

Cell and Gene Therapy: Manufacturing to Market

90 minHall B (L2-HALL-B)
ERKM
Elena Rossi, Kwame Mensah
  • 15:10Shortening Vein-to-Vein Time in CAR-T Manufacturing — Elena Rossi
  • 15:55Outcomes-Based Agreements for One-Off Therapies — Kwame Mensah
15:20
Research Methods

Statistical Pitfalls in Subgroup Analysis

90 minSeminar Room 2.1 (L2-SEM-1)
DRTN
Daniel Reyes, Tomasz Nowak
  • 15:20Judging the Credibility of a Subgroup Effect — Daniel Reyes
  • 16:05Treatment Heterogeneity and Machine Learning: Promise and Caution — Tomasz Nowak